Blood
Protocol: Genomics:
Genomic Analysis using Blood from Gynecological Patients with Cervical Cancer or Cervical Dysplasia
PI: Ron Allison, MD
Brain
Protocol: NCCTG-N0574:
A Phase III Randomized Trial of the Role of the Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with 1 to 3 Cerebral Metastases
PI: Ron Allison, MD
Breast
Protocol: NSABP B-42:
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
PI: Darla Liles, MD
Protocol: ECOG TAILORx Trial:
PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
PI: Darla Liles, MD
Protocol: ECOG 5103:
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node+ and High Risk Lymph Node Negative Breast Cancer
PI: Rachel Raab, MD
Protocol: LJCC 07-03:
A Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple Negative Breast Cancer
PI: Paul Walker, MD
Protocol: LJCC 0801:
Evaluating the Role of Genotype in Tamoxifen Therapy for Breast Cancer
PI: Rachel Raab, MD
Gastrointestinal
Colorectal
Protocol: NSABP FC-4
A Randomized Phase II CT Investigating Irinotecan Plus Cetuximab with or without Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody for the Treatment of Patients with Metastatic K-RAS Wild-Type Carcinoma of the Colon or Rectum that has Progressed on Oxaliplatin and Bevacizumab Given as 1st Line Therapy
PI: Pamela Lepera, MD
Genitourinary
Prostate
Protocol: RTOG 0521:
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer.
PI: Roger Ove, MD
Gynecologic
Cervical
Protocol: AVF3963s:
Neoadjuvant bevacizumab and carboplatin followed by concurrent bevacizumab, carboplatin and pelvic radiation therapy in the primary treatment of cervix cancer
PI: Hiram Gay, MD
Ovarian
Protocol: EC-FV-04:
A Randomized Phase II Trial Comparing EC145 & Pegylated Liposomal Doxorubicin in Comb., vs. PLD Alone in patients with Platinum-Resistant Ovarian Cancer
PI:Howard Homesley, MD
Hemophilia
Hemophilia: SPINART:
A Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis w/rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared to that of Episodic Treatment
PI: Darla Liles, MD
Hematological
Leukemia
Protocol: CALGB 10603:
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) & Consolidation (High-Dose Cytarabine) Chemo + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients<60years old with FLT3 AML
PI: Lillian Burke, MD
Protocol: LJCC 06-05:
Phase II Trial Of Daily Pulse Interleukin-2 With Famotidine In Acute Myelogenous Leukemia
PI: Paul Walker, MD
Liver
Protocol: TheraSphere Device:
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma - HDE#980006
PI: Suzanne Russo, MD
Lymphoma
Protocol: CRAD001N2201:
An Open Label, Single Arm Phase II Study of RAD001 in Patients with Refractory Mantel Cell Lymphoma
PI: Lillian Burke, PI
Lung
Non-small cell
Protocol: ECOG 5597:
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer
PI: Paul Walker, MD
Protocol: LJCC 07-01:
Phase II Trial of Pulsed Paclitaxel with Concurrent Thoracic Radiotherapy and Adjuvant Gemcitabine and Carboplatin in Stage IIIA and IIIB non-Small Cell Lung Cancer
NCI Listing
PI: Hiram Gay, MD
Protocol: MAGRIT 109493:
A Double Blind, Randomized, Placebo Controlled Phase III Study to Assess the Efficacy of recMAGEA3 + AS15 Antigen-Specific Ca Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive NSCLC
PI: Paul Walker, MD
Melanoma
Protocol: ECOG E1697:
Phase III Randomized Study of 4 weeks High Dose IFN-a2b in Stage T3-T4 or N1 (Microsopic) Melanoma
PI: Paul Walker, MD
Pancreatic
Protocol:
A Phase II Study of Direct Tumor Injection of TNFerade Followed by KLH-pulsed Autologous Dendritic Cells in Patients with Unresectable Pancreatic Cancer
PI: Emmanuel Zervos, MD
Protocol:
A Randomized Phase II/III Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
PI: Emmanuel Zervos, MD
Protocol:
A Phase II Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; and Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation for Ras Mutation
PI: Emmanuel Zervos, MD
Photodynamic Therapy
Protocol: PDT ENT:
Photodynamic Therapy in Dysplasia and Carcinoma-in-Situ of the Aero-Digestive tract
PI: Ron Allison, MD
Sickle Cell
Outcome Modifying Genes in Sickle Cell Disease
PI: Charles Knupp, MD
Pharmacology
Protocol: Protherics:
An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment
PI: Lillian Burke, MD
